Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Director departure
|
|
TENAX THERAPEUTICS, INC. (TENX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/15/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/15/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/19/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/01/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/13/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in TENAX THERAPEUTICS, INC. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13D/A
| Rich Stuart reports a 2.3% stake in Tenax Therapeutics, Inc. |
| 02/09/2023 |
SC 13D/A
| Doogan Declan reports a 2% stake in Tenax Therapeutics, Inc. |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Warrant Agency Agreement, by and between Tenax Therapeutics, Inc. and Direct Transfer LLC",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Placement Agency Agreement, by and between Tenax Therapeutics, Inc. and Roth Capital Partners, LLC",
"Form of Securities Purchase Agreement by and between Tenax Therapeutics, Inc. and the purchasers named therein",
"Form of Leak-Out Agreement by and between Tenax Therapeutics, Inc. and the persons named therein",
"Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering CHAPEL HILL, NC, February 03, 2023 — Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of 8,666,666 shares of its common stock and warrants to purchase up to 17,333,332 shares of its common stock at a purchase price of $1.80 per share and associated Public Warrant. The Public Warrants will have an exercise price of $2.25 per share, are immediately exercisable, and will expire five years after their initial exercise date. The offering is expected to close on or about February 7, 2023, subject to customary ..." |
|
| 02/06/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 02/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/02/2023 |
S-1MEF
| Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]: |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/23/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/20/2023 |
8-K
| Other Events Interactive Data |
| 01/06/2023 |
SC 13D/A
| Rich Stuart reports a 9.4% stake in Tenax Therapeutics, Inc. |
| 01/06/2023 |
SC 13D/A
| Doogan Declan reports a 7.9% stake in Tenax Therapeutics, Inc. |
| 01/04/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/11/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction MORRISVILLE, N.C. October 10, 2022 – Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan. The data, collected during the transition from intravenous to oral levosimendan in the open-label extension of the HELP trial, were presented at the Heart Failure Society of America Scientific Sessions 2022, held from October 1 –3, 2022. Title: “The Transition..." |
|
|
|
|